Alpha Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-45,624
Closed -$3.7M 119
2023
Q4
$3.7M Buy
45,624
+1,753
+4% +$136K 0.76% 50
2023
Q3
$3.29M Buy
43,871
+4,982
+13% +$383K 0.77% 50
2023
Q2
$3.34M Hold
38,889
0.83% 47
2023
Q1
$3.34M Hold
38,889
0.83% 47
2022
Q4
$3.34M Buy
+38,889
New +$3.08M 0.83% 47
2020
Q2
Sell
-38,030
Closed -$2.84M 101
2020
Q1
$2.84M Buy
38,030
+953
+3% +$65.9K 1.25% 19
2019
Q4
$2.41M Sell
37,077
-2,808
-7% -$183K 0.89% 45
2019
Q3
$2.53M Buy
39,885
+1,783
+5% +$117K 0.93% 40
2019
Q2
$2.57M Buy
38,102
+287
+0.8% +$18.9K 0.97% 38
2019
Q1
$2.46M Buy
37,815
+1,480
+4% +$98.4K 0.97% 41
2018
Q4
$2.27M Buy
36,335
+821
+2% +$57.4K 1.06% 31
2018
Q3
$2.74M Buy
35,514
+764
+2% +$57.7K 1.1% 24
2018
Q2
$2.46M Buy
34,750
+2,742
+9% +$194K 1% 30
2018
Q1
$2.41M Sell
32,008
-1,030
-3% -$81.9K 1.03% 24
2017
Q4
$2.37M Sell
33,038
-1,007
-3% -$76.5K 1.12% 29
2017
Q3
$2.76M Sell
34,045
-561
-2% -$42.9K 1.31% 14
2017
Q2
$2.45M Buy
34,606
+477
+1% +$31.7K 1.21% 19
2017
Q1
$2.32M Buy
34,129
+5,002
+17% +$352K 1.62% 21
2016
Q4
$2.09M Buy
+29,127
New +$2.16M 1.43% 29

Other funds holding GILD

Alpha Capital Management's GILD Position: Q1 2024 in Review

Alpha Capital Management sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 45,624 shares — an estimated $3.7M sold.

Alpha Capital Management first reported a position in GILD in Q4 2016 and held it in 19 quarters. The position peaked at $3.7M in Q4 2023. 1,721 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

  • Alpha Capital Management reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
  • Alpha Capital Management sold 45,624 Gilead Sciences shares in Q1 2024, an estimated $3.7M.
  • Alpha Capital Management first reported a position in Gilead Sciences in Q4 2016 and held it in 19 quarters.
  • Alpha Capital Management's Gilead Sciences position peaked at $3.7M in Q4 2023.
  • 1,721 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on Alpha Capital Management's 13F filing for Q1 2024, filed 12 Apr 2024.